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The Prevalence and Treatment of Chronic Fatigue Syndrome/ME and Co-morbid Severe Health 
Anxiety / Prevalencia y tratamiento del síndrome de fatiga crónica/EM y ansiedad por la salud 
comórbida 
 
ABSTRACT  
 
Background: Chronic Fatigue Syndrome/ME (CFS/ME) is a debilitating condition that affects 0.2–0.4% 
of the population. Health focussed anxiety is common across medical conditions, and may be relevant in 
CFS/ME. This study sought to identify the prevalence and impact of health anxiety (HA) in CFS/ME and 
evaluate the effectiveness of Cognitive Behavioural Therapy for HA in CFS/ME. Method: Cross-
sectional questionnaire methods and case-series design were used to achieve study aims. Results: 
Analysis indicated that 41.9% of the CFS/ME clinic sample experienced threshold levels of health 
anxiety, which was associated with elevated symptom severity across several dimensions.  Stepwise 
multiple regression indicated physical functioning and depression accounted for 23.8% of variance in 
fatigue; depression, fatigue and HA, accounted for 32.9% of variance in physical functioning. Large 
effect sizes and clinically significant changes were generated in the treatment study. Conclusion: HA is 
common in CFS/ME and likely to exacerbate fatigue and physical functioning. This study identifies HA 
as an important target for treatment, trial findings should be further replicated on a larger scale. 
 
RESUMEN 
Antecedentes: El síndrome de fatiga crónica /ME (SFC/EM) es una enfermedad que afecta al 0,2-0.4% 
de la población. La ansiedad por la salud (HA) es común en condiciones médicas y puede ser relevante en 
el SFC/EM. El objetivo de este fue identificar la prevalencia e impacto de la HA en el SFC/ME y evaluar 
la efectividad de la Terapia Cognitivo Conductual para tratar la HA en el SFC/EM. Método: Se utilizaron 
cuestionarios en base a un diseño transversal y de estudio de casos. Resultados: El 41.9% de la muestra 
clínica de SFC/EM experimentó niveles umbrales de HA, lo que se asoció a una mayor gravedad de 
algunos síntomas. Modelos de regresión lineal múltiple  indicaron que el funcionamiento físico y la 
depresión representaron el 23.8% de la varianza en la fatiga; la depresión, la fatiga y la HA representaron 
el 32.9% de la varianza en el funcionamiento físico. Se identificaron grandes tamaños del efecto y 
cambios clínicamente significativos en el estudio de tratamiento. Conclusión: HA es común en el 
SFC/EM y podría empeorar la fatiga y el funcionamiento físico. Este estudio identifica la HA como 
importante para el tratamiento del SFC/ME. Los resultados de este estudio deberían replicarse a mayor 
escala. 
 
KEY WORDS 
Chronic Fatigue Syndrome; health anxiety; descriptive survey study; experiment; Síndrome de fatiga 
crónica; ansiedad por la salud; estudio descriptivo de la encuesta; experimento 
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Anxiety / Prevalencia y tratamiento del síndrome de fatiga crónica/EM y ansiedad por la salud 
comórbida 
 
INTRODUCTION 
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a debilitating condition 
characterised by excessive fatigue, malaise, muscle pain and unrefreshing sleep, with prevalence rates in 
the region of 0.2-0.4% of the population (National Institute for Health and Care Excellence (NICE), 
2007). It is accepted that the pathogenesis is likely to be a complex interaction which may include 
genetic predisposition, somatic triggers and biopsychosocial factors, however, the aetiology of CFS/ME 
remains poorly understood. CFS/ME can lead to significant disability with subsequent economic costs 
(Rimbaut, Van Gutte, Van Brabander, & Vanden Bossche, 2016). 
 
Despite a number of large CFS/ME treatment trials, a recent meta-analysis (Castell, Kazantzis, & Moss-
Morris, 2011) suggests current treatment options such as Cognitive Behavioural Therapy (CBT) (NICE, 
2007) result in only moderate improvements (g=0.33), contrasting with larger effect sizes for CBT in the 
treatment of other conditions such as anxiety (Olatunji, Cisler, & Deacon, 2010). It has been suggested 
that both the heterogeneity of the condition and moderate treatment response may be attributable to 
phenotypes within the condition which are not being adequately accounted for (Collin, Heron, Nikolaus, 
Knoop, & Crawley, 2018). Treatment success inevitably depends on accurate identification of the 
presenting clinical problem, which is particularly challenging in conditions where co-morbidity is high; 
a recent systematic review and meta-analysis reported around half of the CFS/ME population report 
anxiety and/or depression (Caswell & Daniels, 2018) which supports existing findings. These rates are 
comparable with other long-term health conditions such as Diabetes and Chronic Obstructive Pulmonary 
Disorder (Campbell-Sills et al., 2013).  
 
The overlapping characteristics of depression and CFS/ME continue to be discussed and supported 
(Janssens et al., 2015) however, anxiety in CFS/ME has been largely neglected. Conversely, Health 
anxiety has gained significant interest due to high prevalence rates of up to 24.7% (Tyrer et al., 2011) in 
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medical settings, compared to 0.26-8.5% in the primary care population (Creed & Barsky, 2004). A 
recent study reported incidence of health anxiety in CFS/ME at 42% (Daniels, Brigden, & Kacorova, 
2017), however this study was limited in sample size and scope of investigation.  There is a growing 
body of evidence supporting the use of the CBT health anxiety model (CBT-HA) in medical 
populations, showing effective outcomes (Tyrer et al., 2017). CBT-HA is based on the notion that 
ambiguous health-relevant stimuli are subject to interpretation which inform behavioural responses such 
as hypervigilance to physiological sensations, avoidance, bodily monitoring and reassurance seeking in 
order to prevent realisation of health concerns, however these strategies often increase distress.  These 
behavioural strategies may feel necessary and justified in a condition such as CFS/ME where diagnosis 
is often protracted and delegitimising. The utility of the CBT-HA model in CFS/ME has recently been 
tested in a single case study, reporting successful outcomes at 12 months (Daniels & Loades, 2017). 
With current recommended interventions for CFS/ME offering modest outcomes and emerging reports 
of elevated rates of health anxiety, CBT-HA may offer an alternative treatment to those presenting with 
co-morbidity in CFS/ME.  
 
This study seeks to replicate and advance previous findings to examine the presence, impact and 
treatment of health anxiety in CFS/ME.      
 
Study One  
 
Aims were to replicate earlier findings and seek supportive evidence for the treatment of co-morbid health 
anxiety in CFS/ME. More specifically, to (a) identify the prevalence of anxiety, depression and health 
anxiety in CFS/ME and (b) assess the relative impact of health anxiety on the primary outcome measures 
in treatment for CFS/ME, fatigue and physical functioning.    
  
METHOD 
Participants 
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All patients referred within the sampling period were invited to complete questionnaires prior to initial 
assessment. This formed the battery of measures for this study. Inclusion criteria were: (a) aged 18 or 
over (b) definite diagnosis of CFS/ME (c) literate in the English language. 
 
Sample characteristics 
During the 12 month sampling period, 423 patients were referred to the service. Of those, 283 participants 
were eligible for participation due to receiving a definite primary diagnosis of CFS/ME (Figure 1, 
CONSORT diagram), falling within the age range and indicating sufficient understanding of the English 
language. Sixty-one percent (n=172) both consented and completed the SHAI; the remaining declined 
without reason. Standard imputation methods were required for missing data in eight cases.  
 
(insert Figure 1 about here) 
 
Figure 1. CONSORT Diagram of CFS/ME health anxiety prevalence study  
 
As described in Table 1, the final sample were mostly female, white British with ages ranging from 17-70 
years. Months since onset of fatigue was available for 135 participants (78%) and ranged from 5 – 312 
months, with a mean duration of 60 months. Age and months since onset were correlated using Spearman’s 
Rho (due to lack of normality in the data and multimodal distribution) however no significant association 
was found (rs=.145, p = .93) and therefore not further controlled for.  Of those who responded to the 
demographic assessment questions on co-morbidity (average of 64% across questions), 30% indicated 
comorbid migraine, 41.5% irritable bowel syndrome, 16.5% fibromyalgia;<1% chronic regional pain 
disorder, 44.2% anxiety, depression 48% and ‘other’ co-morbidities unlisted 28.4% (n=29). The latter 
included pain related disorders (n=12) neurological problems (n=4) mental health disorders (n=4) vitamin 
deficiencies (n=3).  
 
[insert Table 1 about here] 
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Instruments 
Information regarding demographic and existing medical information was collected using the routine 
clinic assessment form used. In addition to this, the questionnaire battery included the following 
standardised instruments: 
 
The 11-item Chalder fatigue questionnaire (Chalder et al., 1993) measures physical and mental fatigue. 
Reliability and validity of this measure is supported in CFS/ME (Deale, Chalder, Marks, & Wessely, 
1997). The 0-3 scoring method was used as it is considered more sensitive to change. 
 
The 14-item Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) measures 
anxiety and depression in two sub-scales. Reliability has been demonstrated CFS/ME samples (α = .80, 
.84 respectively) (Daniels et al., 2017).  
  
The Short Form-36 (SF-36) physical functioning scale measures functioning as a result of 
physical/emotional difficulty (Jenkinson, Coulter, & Wright, 1993); the SF-36 has good test–retest 
reliability score  (r = .75) (Brazier et al., 1992). Higher scores indicate better functioning. 
 
The Epworth Sleepiness Scale (Johns, 1991) measures likelihood of dozing/sleepiness in specific 
situations, rating 0-3. Test–retest reliability (r = .82), and internal reliability (α = 0.88) were good (Johns, 
1992).  
 
In addition to the standard battery of questionnaires, the 14-item Short Health Anxiety Inventory (SHAI) 
(Salkovskis, Rimes, Warwick, & Clark,   2002) was included for the purposes of this study. This measure 
was deemed the most suitable measure to assess health anxiety due to the robust theoretical basis of the 
measure, with items directly derived from the evidence-based empirically-grounded clinical model of 
health anxiety (Salkovskis et al. 2003), aligning with the now commonly accepted anxiety foundation of 
health anxiety/hypochondriasis (rather than somatization or more generic underpinnings seen in other 
similar measures; see Salkovskis et al. 2002).  According to the original paper, the conceptual construct of 
health anxiety is based on the principle that distress arises due to an enduring predisposition to 
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misinterpret ambiguous normal bodily variations or physiological stimuli as indicators of physical illness 
(which may also extend to medical information) resulting in the employment of behaviours which serve 
to maintain rather than reduce distress. The items relate directly to the specific dimensions of the 
cognitive model as set out in Salkovskis et al.(2003), including preoccupation with health concerns, 
vigilance to bodily sensations, interpretation of ambiguous physical sensations and disbelief in medical 
rassurance. The original paper utilised standard deviations of normative data to produce clinical cut-offs 
to indicate case (>18) and non-case levels of health anxiety and differentiate generic anxiety. Subsequent 
studies and reviews have established test-retest reliability, concurrent, convergent and discriminant 
validity of the SHAI (Hedman et al. 2015, Daniels et al. 2017). Overall internal consistency of the 
measure is very good (α = .89) (Rabiei, Kalantari, Asgari, & Bahrami, 2013; Salkovskis et al., 2002) and 
the measure has also been demonstrated as reliable in CFS/ME (α =.89) (Daniels et al., 2017) and other 
medical conditions (Tyrer et al. 2011).  
 
 
Procedure 
Cross-sectional questionnaire data were taken from a specialist CFS/ME service over a 12 month period 
from March 2016 to March 2017. The service offers assessment and treatment in accordance with NICE 
(2007) guidance, patients are diagnosed using the Fukuda criteria checklist (Fukuda, et al. 1994).  Ethical 
approval was granted for the prevalence study and case series from the University of Bath and Cornwall 
and Plymouth Research Ethics Committee (REC no: 13/SW/006) and East Essex Research Ethics 
Committee (13/EE/0301) respectively.   
 
Data analysis was completed using Statistical Package for Social Sciences (SPSS) v23. Internal 
consistency of the SHAI was tested using Cronbach’s alpha and item-total correlations to support the 
utility and reliability of the SHAI in the CFS/ME population.  
 
To assess prevalence of health anxiety, a score of >18 was used as a cut off for definite cases of health 
anxiety, replicating previous work (Daniels et al., 2017) and research in similar fields (Carrigan, Dysch, 
& Salkovskis, 2018). To assess prevalence of anxiety and depression using the HADS, the predefined cut-
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off of >11 was used to indicate case level distress (Brennan, Worrall-Davies, McMillan, Gilbody, & 
House, 2010). A chi-squared test compares the prevalence rates of health anxiety in CFS/ME in 
comparison to other medical settings. 
 
Independent samples t-tests examined differences between those with high health anxiety (HiHA) versus 
those with low health anxiety (LoHA) across all variables. An upper cut-off of definite case >18 on the 
SHAI was used, with a <14 lower cut-off allowing a comparison of distinct groups at either end of the 
distribution. Scores of 15-17 on the SHAI represents sub-clinical borderline health anxiety and were thus 
excluded from the sub-group analysis.  
 
Planned a priori Pearson’s tests of association were performed to examine the relationship between health 
anxiety, fatigue and physical functioning, plus age and duration to assess whether the latter should be 
controlled for in analysis.  
 
Stepwise multiple regressions was performed to establish the r2 variance of each of the independent 
predictor variables on the pre-specified dependent criterion variables.  The predictor variables were 
HADS-A, HADS-D and of focal interest, health anxiety as measured by the SHAI. The criterion variables 
were the Chalder Fatigue questionnaire and SF-36 for physical functioning, respectively. Given the 
theoretical and evidenced link between fatigue and physical functioning, fatigue was also included as a 
predictor variable for physical functioning, and vice versa.   
 
A significance value of p < .05 was planned for all analyses except tests of association where multiple 
comparisons indicated a significance threshold of p < .0125. 
 
 
RESULTS 
Data analysis  
Data from the SHAI were normally distributed. The SHAI was found to have high internal-consistency in 
this population (14 items; α=0.86); tests of convergent validity between the HADS-A and SHAI 
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confirmed moderate convergence (r=.476, n=169, p <.001), similar to previous tests of convergence in 
CFS/ME (Daniels et al., 2017). Score on the SHAI ranged from 4 - 38 (M=16.65, SD=6.45), with 41.9% 
of the sample reaching SHAI clinical cut-off for definite case health anxiety (>18). This is significantly 
higher (p< .001) than prevalence in a Neurology outpatient sample (N=3205, 24.7%) (Tyrer et al., 2011), 
the most elevated across outpatient medical clinics.  
 
Analysis of HADS data indicated 40.7% (n=70) and 38.6% (n=66) reached ‘definite’ caseness in terms of 
anxiety and depression respectively (>11), (excluding missing data cases), consistent with rates of self-
reported diagnosis of anxiety (33.1%) and depression (35.5%) on the clinic assessment form.    
 
Independent t-test comparisons between HiHA and LoHA groups (n=69, n=72 respectively) were 
performed with equal variances noted on all variables except age and SHAI where variance adjustments 
were made. Significant differences were found between groups in the expected directions on all measures 
of interest: Chalder fatigue questionnaire (t(135)= -3.24, p=.002), SF-36 (t(138)=4.83, p<.001). Analysis 
indicated that those with case level health anxiety demonstrated significantly lower physical functioning 
and mood and higher levels of fatigue, sleepiness and anxiety than those without case level health 
anxiety. Age between groups was not significant (t(136.12) = 1.59, p =.115). HiHA group mean scores 
for the HADS-A and HADS-D fell within the ‘severe’ range (>11) whereas LoHA group means did not.   
 
Pearson’s test of association indicated significant relationships between the SHAI and the SF-36 (r=-.337, 
N=170, p<0.001) and Chalder fatigue questionnaire (r=.195, N=167, p=0.01), HADS-A (r=.476, N=169, 
p<0.001) and HADS-D (r=.384, N=171, p<0.001) in expected directions. The association between the 
SHAI and Epworth Sleepiness Scale was non-significant at predetermined levels (r=.183, N=167, 
p=0.018).   
 
Stepwise regression analysis indicated physical functioning and depression accounted for 23.8% of the 
variance of fatigue (R2=.238, F(2, 160)=24.61, p<.001). Physical functioning accounted for 20.7% of the 
variance (β=.-455, p<.001), depression accounted for an additional R2 change of 3% (β=.196, p =.014) 
(see Table 2). All other variables entered were excluded from the model.  
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[insert Table 2 about  here] 
 
Three significant predictors accounted for 32.9% of the variance of physical functioning (R2=.329, 
F(3,160)=25.62, p<.001). Depression explained 21.8% (β=-.467, p<.001) followed by fatigue (β = -.328, 
p <.001) and health anxiety (β = -.141, p =.044) (Table 3). Health anxiety contributed r2 change of an 
additional 3.2% after accounting for depression and fatigue, indicating health anxiety was a significant 
independent predictor of physical functioning. All other variables entered were excluded from the model.  
 
[insert Table 3 about here] 
 
Study Two 
 
Aims were to assess the relative effectiveness of a CBT-HA intervention for CFS/ME and co-morbid 
health anxiety, replicating earlier findings on a larger scale.  
 
METHOD 
 
Participants  
Patients were eligible for referral to the treatment trial if they met criteria for study one, plus achieving a 
score of >18 on the SHAI at assessment. Those with co-morbidities were not excluded if their primary 
concern was CFS/ME. An idiosyncratic CBT-HA treatment derived formulation collaboratively 
developed with each individual provided the basis for the treatment intervention, integrating CFS-
associated symptoms and health anxiety-related symptoms. The CBT-HA treatment comprised twelve 
individual face-to-face 60 minute sessions, replicating earlier work described by Daniels & Loades 
(2017). Treatment was delivered by the first author (JD), an experienced clinical psychologist and 
accredited cognitive behaviour psychotherapist, with in-vivo supervision and protocol fidelity monitoring 
from health anxiety expert Professor Paul Salkovskis. Both participants and clinician audio recorded all 
treatment sessions.   
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Instruments 
Participants completed all study one battery of questionnaires, with the addition of the three level EQ-5D 
health related quality of life questionnaire (EuroQol Group, 1990). Measures were repeated weekly 
during the baseline period to establish stability of symptoms, and at each treatment session. 
 
Procedure 
A consecutive case-series with phased AB design was used, with phase ‘A’ representing a six week 
baseline phase requiring completion of weekly measures only, and phase ‘B’ representing the intervention 
phase. The n of 1 design is a suitable approach to pilot and test feasibility of complex interventions as 
fore-runners to large multi-centre randomised controlled trials (Medical Research Council 2006).  
 
For analysis, reliable and clinically significant change on each measure was calculated using the Jacobson 
and Truax (1991) method (Jacobson & Truax, 1991). Change is calculated based on pre-treatment 
measures (session 1) and final treatment measures (session 12). Cohen’s d was calculated per measure for 
the combined group to give an indication of overall treatment effect, dividing the mean change in 
individual scores by the pooled standard deviation of scores at time points (pre-treatment, end of 
treatment). Further statistical analyses were not planned as this was not considered to offer further 
meaningful interpretation of the data and was considered scientifically unjustified given sample size and 
appropriateness of aforementioned planned analysis.  
 
Description of treatment: CBT-HA 
CBT-HA is a formulation-driven cognitive behavioural intervention for health anxiety as described in 
Salkovskis, Warwick, and Deale (2003). 
Following assessment of relevant factors such as onset, duration and relevant background, the initial 
sessions were used to formulate an idiosyncratic CBT-HA model that integrated individual patients’ 
reported CFS-associated symptoms (e.g. fatigue and pain in ‘physical’ domains) and health anxiety-
related symptoms (e.g. palpitations). Details of a recent episode of CFS/ME symptoms, cognitions, 
associated behavioural and emotional responses (e.g. anxiety) were elicited to populate the individualised 
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formulation. In CBT-HA, cognitions related to health concerns (e.g. I will collapse) trigger behavioural 
responses designed to prevent the feared outcome. However, these (safety seeking) behaviours (SSB) 
serve to prevent disconfirmation of the feared outcome, thus reinforcing the behaviour through operant 
mechanisms.  The CBT-HA formulation draws out the unintended consequences of the SSB (e.g. 
anxiety/frustration, intensified pain/deconditioning) and how these further reinforce fear of ‘collapse’, for 
example. This creates a vicious self-reinforcing cycle of distress which is maintained by SSB originally 
employed to reduce the likelihood of physical collapse or other feared outcome.     
This formulation formed the basis for treatment. Standard CBT techniques such as use of ‘hypothesis A 
vs. Hypothesis B’, verbal reattribution, cognitive restructuring and so forth, were used to shift negative 
self-referential beliefs, test SSB and develop more adaptive self-management strategies.   The CBT-HA 
approach was not adapted for the CFS/ME population; physical symptoms, beliefs and behaviours 
associated with CFS/ME were included within the standard dimensions of the model, with the same 
techniques used for those with and without medical problems, as seen in Tyrer et al. (2017). 
 
RESULTS 
 
Sample characteristics 
Thirty consecutive referrals were made to the treatment trial by clinicians within the service. Of these, 
seven did not meet inclusion criteria at screening, a further four reported logistical reasons for declining 
therapy (e.g. competing work demands) and one preferred a standard CFS/ME intervention. This left 
eighteen meeting eligibility criteria who consented to entry into the trial. Thirteen progressed to 
assessment after five were lost to follow up. Prior to treatment commencement, two further participants 
were withdrawn due to no longer meeting the eligibility criteria (n=2) and one withdrew for 
personal/social reasons (n=1). The final sample consisted of the pre-specified target of n=10 participants, 
63% of the eligible sample. Recruitment ceased once n=10 had been reached.  
 
Data from the clinical assessment form indicated all participants were female, ages ranging from 19-56 
years, with duration of onset of CFS/ME 6-96 months (Table 1). Participants reported pain (n=3), anxiety 
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(n=6) and depression (n=2) in addition to CFS/ME. None had previous experience of therapy. Four 
participants were in full time (>30 hours per week) or graded return to full time employment (40%), four 
in part-time employment (40%), one was a student (10%) and one was unemployed (10%). 
 
Analysis   
Eight participants completed the full course of therapy (80%, n=8). All those who completed treatment 
(n=8) demonstrated reliable change (RC) and clinically significant change (CSC) on at least one primary 
outcome: six of eight achieved RC and seven of eight CSC on the Chalder fatigue questionnaire; all 
treatment completers (n=8) achieved both RC and CSC on the SHAI and moved to non-case status. 
Relevant data required to calculate the RC on the SF-36 or EQ-5D was not available, however treatment 
completers improved by 20-50 points, with six of eight achieving CSC (see Table 5). For those who did 
not complete treatment (n=2; withdrawal at session 5 and 6) scores remained stable: neither participant 
demonstrated point change on the Chalder fatigue questionnaire; no follow-up data was returned on the 
SF-36 or EQ-5D. The SHAI either remained the same or reduced by 2 points.  CSC and RC were not 
calculated for these participants as it was evident that a partial intervention had elicited no change.    
 
Calculations of Cohen’s d included all participants, including those who withdrew from treatment. 
Analysis of data indicated large effect sizes of >0.8 on each measure with the exception of HADS-D 
which fell marginally shy of the cut-off (0.75). Cohen’s d for the effect of treatment on the EQ-5D and 
SF-36 were based on the data available for the n=8 treatment completers as these were pre/post measures.  
 
[insert Table 4 about here] 
 
Figure 2 reports the data path of the median values of key measures (SHAI, Chalder fatigue 
questionnaire) during phase A (baseline) and phase B (treatment) for those who completed treatment 
(dotted line denotes clinical cut off of the SHAI). Physical functioning is not represented due to scaling.  
 
[insert Figure 2 about here] 
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Figure 2. Median Baseline and Treatment Ratings of Health Anxiety (SHAI) and Fatigue (Chalder 
fatigue questionnaire 
 
DISCUSSION 
The overarching objectives of this study were to replicate and extend previous findings examining the 
prevalence, relative impact and treatment of CFS/ME with co-morbid health anxiety using larger-scale 
more robust studies to inform future treatment development and advance research in the field.  
 
Findings from study one indicate that health anxiety in CFS/ME is common and significantly associated 
with symptom severity. Participants with high health anxiety were more fatigued, anxious and depressed, 
demonstrating lower levels of physical functioning than those without; health anxiety was confirmed as a 
significant predictor in a three factor model of physical functioning, but not at all in fatigue. Overall, 
findings from study one support, replicate and extend previous work (Daniels et al., 2017) suggesting 
health anxiety in CFS/ME is highly prevalent, significantly more so than in other medical settings (Tyrer 
et al., 2011) but similar to those found in the chronic pain population (Rode et al., 2006). The 
commonality between the chronic pain and CFS/ME population may be attributed to the absence of a 
unifying theory to underpin and explain persistent physical symptoms that are heterogeneous in nature; 
the chronicity associated with ‘chronic’ pain and ‘chronic’ fatigue syndrome may present fertile breeding 
ground for health focussed anxiety where other relevant factors co-exist, particularly considering the 
additional lack of validation in CFS/ME (Dickson, Knussen, & Flowers, 2007).   
 
Physical functioning accounted for 20.7% of the variance of fatigue, supporting current theories of a 
relationship between these factors and established clinical notions, suggesting that reduced physical 
activity may perpetuate and exacerbate fatigue during activity as seen in other conditions such as arthritis 
(Hegarty et al., 2015). Reciprocally, the presence of fatigue is likely to reduce both motivation and 
compromise capacity for physical functioning, presenting as a vicious cycle which forms a key barrier to 
clinical intervention. This assumption forms the basis of behavioural and physical activity based 
interventions for CFS/ME. Depression was a secondary significant predictor of fatigue at a lower 
proportion of variance (an additional 3%), and was the most significant predictor of physical functioning.  
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This is unsurprising given the association between low mood and reduction in physical activity, the 
subsequent muscle deconditioning that follows from avoidance of physical activity, and then increased 
fatigue at lower levels of exertion (Browne & Chalder, 2006). Chronic health problems such as CFS/ME 
are likely to impair mood and physical functioning, which perpetuate both physical symptoms such as 
fatigue and psychological distress. However, these findings coupled with rates of co-morbidity suggest 
that standalone screening for depression may be warranted.   
 
General anxiety was not found to be a significant predictor of fatigue or physical functioning, where 
health anxiety has been found to be an independent significant predictor of the latter, albeit accounting for 
only a marginal proportion of the variance. However, taken with significant findings relating to higher 
physical and psychological distress in the high health anxiety group, this area warrants further 
exploration. Previous research suggests that anxiety and health anxiety are distinct yet related constructs 
(Daniels et al., 2017), with the present findings offer replication and advancement in the precision of our 
current understanding of the potential impact and co-morbid of anxiety and health anxiety in CFS/ME.  
More specifically, due to unexplained bodily sensations, lack of reassurance from medical practitioners 
(due to the condition being poorly understood) and the complex problematic nature of managing fatigue, 
patients with CFS/ME may be employing strategies to prevent worsening of symptoms such as restricting 
and/or avoidance of physical activity, attention to ‘warning signs’ or excessive rest (Daniels & Loades, 
2017;  DeGucht et al. 2017), subsequently resulting in lower levels of physical functioning and fatigue on 
exertion. This is consistent with models of health anxiety (Salkovskis et al., 2003) and fear-avoidance 
models (Vlaeyen et al., 2016) and is seen elsewhere in other medical conditions such as Multiple 
Sclerosis (Hayter et al., 2016) where there is a clearly understood pathogenesis; indeed we suggest that 
CFS/ME presents similarly. Findings support these clinical hypotheses, however further work is needed 
to elucidate the mechanisms and direction of effects when health anxiety co-occurs with CFS/ME. 
 
Study two replicates and further tests the utility of CBT-HA in a larger CFS/ME sample.  Outcomes are 
consistent with recent findings indicating that CBT-HA is an appropriate and effective treatment for 
health anxiety comorbid with medical conditions (Cooper, Gregory, Walker, Lambe, & Salkovskis, 
2017), despite the potential complex interaction between CFS/ME and health anxiety. Treatment 
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outcomes demonstrate high levels of both reliable and clinically significant change in the target measures, 
with large effect sizes across the majority of measures indicating effectiveness of the intervention. This 
offers preliminary evidence that a protocolised intervention for a complex presentation such as CFS/ME 
demonstrates utility and a credible basis for psychological intervention. Despite the complex symptomatic 
presentation of CFS/ME and health anxiety co-occurring, the intervention was unproblematic and 
protocol driven. It is imperative that those receiving the intervention understand that the implicit 
assumptions of the model does not discriminate between conditions; health anxiety is prevalent and 
responsive to effective treatment across medical conditions; the focus is distress and does not infer 
causality.   
 
Limitations and future research 
A proportion of clinicians and patients within the prevalence study expressed scepticism relating to the 
SHAI, which may have subjected recruitment to selective bias from clinicians with positive/neutral views 
of the SHAI, leaving opportunity for inadvertent sampling bias of psychologically receptive participants 
only. Data was collected prior to diagnosis, a potentially anxious time, however the SHAI requires data 
based on the ‘past week’ and has good test-retest reliability in medical settings. Health anxiety was not 
confirmed using formal diagnostic procedures; a larger, longitudinal treatment study using diagnostic 
interviews such as the structured clinical interview for the diagnostic statistical manual (SCID) or similar 
would advance a more complex and robust understanding of the impact and potential mediating role of 
health anxiety in treatment, featuring these findings as a firm theoretical basis for development in this 
area.   
 
The case-series n of 10 represents an adequately sized sample proportionate to the methodology, with 
significant outcomes across several dimensions, however a RCT using formal diagnostic procedures and 
control comparisons would generate further evidence to support the utility of CBT-HA in CFS/ME and 
would both satisfy current study limitations and offer a logical next step in the field.  
 
CONCLUSIONS 
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This is the first study to robustly examine prevalence rates of health anxiety in CFS/ME, acting as a larger 
scale replica of previous studies. Outcomes from both the prevalence study and treatment trial make a 
novel contribution to the current understanding and treatment of health anxiety and co-morbidity in 
CFS/ME. This study provides a clear rationale and platform for further research to replicate and enhance 
treatment options to this clinical population.  
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FIGURE LEGENDS  
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Figure 1. CONSORT Diagram of CFS/ME health anxiety prevalence study  
Figure 2. Median Baseline and Treatment Ratings of Health Anxiety (SHAI) and Fatigue (Chalder 
fatigue questionnaire) for treatment completers 
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TABLES 
 
Table 1 
Demographic and Clinical Variables for Study One and Study Two  
 Study One 
N<172 
 
Mean (SD) 
Study Two 
N=10  
 
Median (IQR) 
Age (years)   38.6 (12.7) 32 (12.41) 
Female, n (%) 147 (86%) 10 (100%) 
Median duration of illness, months (IQR) 59.55 (14, 72)  36 (12-96) 
British ethnicity  167 (97%) 10 (100%) 
SHAI 16.65 (6.45) 26.3 
Number of Pts reaching case level SHAI (%) 41.9 100 
HADS-A   9.73 (4.45) 12 
Number of Pts with HADS-A (%) score >11 40.7 80 
HADS-D  9.36 (4.06) 8.8 
Number of Pts with HADS-D (%) score >11 38.6 40 
Chalder fatigue questionnaire  27.11 (4.71) 10.5 
SF-36 45.18 (25.91) 39.3 
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Table 2 
Summary of Stepwise Multiple Regression Analysis for Variables Predicting Fatigue   
 
 Model 1 Model 2 
Variable Unstandardised  
co-effients 
CE 
Beta  
Unstandardised  
co-effients 
CE 
Beta  
Beta SE Beta Beta SE Beta 
Physical 
functioning 
-.085 .013 -.455 -.068 .015 -.364 
Depression    -.236 .094 -.196 
R2  .207   .238  
F for change 
in R2 
 41.62**   6.24*  
*p=.014 
**p<.001 
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Table 3 
Summary of Stepwise Multiple Regression Analysis for Variables Predicting Physical Functioning 
 
 Model 1 Model 2 Model 3 
Variable Unstandardised  
co-effients 
CE 
Beta  
Unstandardised  
co-effients 
CE 
Beta  
Unstandardised  
co-effients 
CE 
Beta  
Beta SE Beta Beta SE Beta Beta SE Beta 
Depression -3.022 .453 -.467 -2.245 .459 -.347 -1.903 .486 -.294 
Fatigue     -1.1767 .282 -.328 -1.731 .379 -.322 
Health 
anxiety  
      -.552 .278 -.141 
R2  .218   .312   .329  
F for change 
in R2 
 44.45**   21.43**   3.95*  
*p =.044 
**p >.001 
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Table 4 
Calculation of Effect Size, Reliable and Clinically Significant Change of CBT-HA for CFS/ME 
Measure Baseline 1 
M (SD) 
Last 
baseline/pre-
treatment  
M (SD) 
End of 
therapy  
M (SD) 
Change 
Pre-post 
M (SD) 
Reliable  
Change 
n 
Clinically  
Significant  
Change 
n 
Effect 
size 
pre-post 
d 
  
Chalder 
Fatigue 
Score  
26.70 
(4.52) 
26.70 (4.79) 14.90 
(10.26) 
11.80 
(9.45) 
6  7  1.47 
SHAI  25.70 
(5.31) 
26.40 (6.98) 14.30 
(11.38) 
12.10 
(7.87) 
8  8  1.28 
HADS-A 13.40 
(3.27) 
13.10 (3.35) 7.6 
(6.54) 
5.5 (4.50) 5  7  1.06 
HADS-D 11.20 
(3.99) 
10.20 (3.99) 6.6 
(5.54) 
3.60 
(3.78) 
3  6  0.75 
EQ-5D* - 8.88 (1.36) 7.38 
(1.85) 
1.5 (0.92) - - 0.93 
SF-36* - 46.88 (25.35) 74.38 
(22.43) 
27.50 
(13.63) 
- 6  1.15 
*Calculations based on n=8 treatment completers due to missing end of therapy measures for n=2 
 
 
